文献速递甲状腺疾病

左甲状腺素联合丙硫氧嘧啶治疗儿童单羧酸转运体8缺陷:12例多中心病例系列

Combined Levothyroxine and Propylthiouracil Treatment in Children with Monocarboxylate Transporter 8 Deficiency: A Multicenter Case Series of 12 Patients.
PubMed 文献 · Thyroid · 2024-09-30

这项多中心病例系列纳入12例接受丙硫氧嘧啶(PTU)联合左甲状腺素(LT4)治疗的男性单羧酸转运体8(MCT8)缺陷患儿,数据收集自2008年1月至2024年6月24日。PTU在平均6.8 mg/kg/day剂量下使总三碘甲状腺原氨酸(TT3)浓度降低25%,LT4在平均4.3 µg/kg/day剂量下使游离甲状腺素(fT4)浓度较基线升高40%。联合治疗使血清T3、fT4和总甲状腺素(TT4)正常化,观察期间未发现对肝功能或粒细胞数量的不良影响。

要点

  • PTU在平均6.8 mg/kg/day剂量下使TT3浓度降低25%,LT4在平均4.3 µg/kg/day剂量下使fT4较基线升高40%。
  • 联合治疗使MCT8缺陷患者的血清T3、fT4和TT4正常化,治疗中促甲状腺激素浓度检测不到。
  • 观察期间未发现对肝功能或粒细胞数量的不良影响,个体化剂量调整对达到治疗目标至关重要。

核心结论

  • PTU与LT4联合治疗使MCT8缺陷患者的血清T3、fT4和TT4正常化,个体化剂量调整对达到治疗目标至关重要,提示需要个性化治疗方案。

研究设计与样本

  • 多中心病例系列,纳入12例父母或监护人同意接受PTU和LT4治疗的男性MCT8缺陷患者,数据收集自2008年1月至2024年6月24日。
  • 分析基线和末次访视的生化、代谢和人体测量参数,统计方法包括Wilcoxon符号秩检验、广义估计方程和受试者工作特征曲线。

主要发现

  • 患者血清总三碘甲状腺原氨酸(TT3)浓度和TT3/TT4比值显著降低,血清总甲状腺素(TT4)和游离甲状腺素(fT4)浓度升高。
  • PTU在平均6.8 mg/kg/day剂量下使TT3浓度降低25%,LT4在平均4.3 µg/kg/day剂量下使fT4浓度较基线升高40%。
  • 治疗中促甲状腺激素浓度检测不到。
  • 总体上基线与末次访视之间代谢和体格参数无统计学差异,但在有这些数据的8例患者中有6例体重(z评分)增加。
  • 观察期间未发现对肝功能或粒细胞数量的不良影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the combined administration of propylthiouracil (PTU) and levothyroxine (LT4) in managing monocarboxylate transporter 8 (MCT8) deficiency and identify optimal therapeutic dosages. Methods: This multicenter case series involved 12 male patients with MCT8 deficiency whose parents/guardians consented to PTU and LT4 treatment. Data were collected from January 2008 to June 24, 2024. The study focused on treatment safety and outcomes, analyzing baseline and last encounter biochemical, metabolic, and anthropometric parameters. Statistical analyses included Wilcoxon signed ranks tests and generalized estimated equations to assess effects on thyroid and metabolic markers, and receiver operating characteristics curves to predict optimal dose. Results: Patients showed a significant reduction in serum total triiodothyronine (TT3) concentration and TT3/TT4 ratio, with increased serum TT4 and free T4 (fT4) concentrations. The use of PTU effectively reduced TT3 concentration by 25% at an average dose of 6.8 mg/kg/day, while LT4 increased fT4 concentration by 40% from baseline at an average dose of 4.3 µg/kg/day. Thyrotropin concentration was undetectable on treatment. No statistical differences were observed in metabolic and physical parameters between baseline and last encounter overall for the group, but six of eight patients for whom these data were available had an increase in weight (z-score). There were no adverse effects on liver function or granulocyte numbers noted throughout the period of observation. Conclusion: Combined treatment with PTU and LT4 normalized serum T3, fT4, and TT4 in patients with MCT8 deficiency. Individualized dose adjustments were crucial for achieving therapeutic goals, indicating the need for personalized treatment plans.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Weiss RE, Lemos JRN, Dumitrescu AM, et al. Combined Levothyroxine and Propylthiouracil Treatment in Children with Monocarboxylate Transporter 8 Deficiency: A Multicenter Case Series of 12 Patients. Thyroid. 2024. PMID: 39283825. doi:10.1089/thy.2024.0285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。